Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Ausztrália1. fázis

Study to Assess the Safety and Pharmacokinetics of AVD275 Injection in Patients With Osteoarthritis of the Knee

A legfontosabb adatok

Ki végzi
Avidence Therapeutics
Hol
Wahroonga (Ausztrália)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
1. fázis
Résztvevők
20 fő, tervezett
Kezdés
2026. jan. 22.
Várható befejezés
2027. máj.
A vizsgálat típusa
Beavatkozással járó, 3 csoport
A vizsgált kezelések
  • AVD275 Intra-articular Injection
A regiszteradat frissítve
2026. október 20.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with knee osteoarthritis (wear-and-tear arthritis of the knee). They get one injection of AVD275, a form of celecoxib, into the knee.

Életkor
20 to 75 years
Nem
Men and women
A betegség stádiuma
Knee osteoarthritis symptoms for 6 months or more. Kellgren-Lawrence Grade 1-4 on a knee X-ray. Must meet ACR criteria for osteoarthritis. BMI ≤ 40 kg/m2. Able to walk and in good general health.
Korábbi kezelés
No steroid or NSAID injection into the knee within 2 months. No hyaluronic acid or Zilretta injection into the knee within 3 months. No steroid pills or muscle injections within 1 month. No opioids within 2 weeks, except tramadol and tapentadol. No knee replacement in that knee.

A részvétel fő kizáró okai

  • Other joint diseases such as rheumatoid arthritis, gout or fibromyalgia
  • Knee surgery or injury in that knee in recent months, or surgery planned during the study
  • Heart or blood vessel disease, or a 10-year ASCVD risk ≥10%
  • Allergy to NSAIDs (including celecoxib), sulfonamide drugs or lidocaine
  • Pregnant or breastfeeding women

A regiszter feltételei, szó szerint

Mind a 32 feltétel megnézéseKevesebb

Ki vehet részt

  • Written consent to participate in the study; Willingness and ability to comply with the study procedures, visit schedules and follow verbal and written instructions
  • Male or female: 20 years to 75 years of age
  • Symptoms associated with OA of the knee for ≥6 months prior to screening (patient reported is acceptable); Knee OA may be unilateral or bilateral
  • Currently meets ACR Criteria (clinical and radiological) for OA as follows:; Knee pain; At least one of the following:; Age > 50 years; Stiffness < 30 minutes; Crepitus; Osteophytes
  • Kellgren-Lawrence (K-L) Grade 1-4 in the index knee based on X-ray performed during screening (locally read) within 6 months from screening
  • Body mass index (BMI) ≤ 40 kg/m2
  • Ambulatory and in good general health

Ki nem vehet részt

  • Intra-articular corticosteroids or intra-articular nonsteroidal antiinflammatory drugs (NSAIDs) (investigational or marketed) in the index knee within 2 months of screening; Intra-articular hyaluronic acid (investigational or marketed) in the index knee within 3 months of screening; Intra-articular Zilretta within 3 months of screening
  • Intramuscular or oral corticosteroids within 1 month of screening
  • Patients who received opioids (excluding tramadol and tapentadol) within 2 weeks of screening
  • Any other investigational drug/biologic use within 3 months of screening
  • Prior diagnostic arthroscopy to the index knee within 3 months of screening; Prior arthroscopic or open surgery of the index knee (including microfracture and meniscectomy) within 6 months of screening;Prior regenerative joint procedures on the index knee, including, but not limited to, stem cells transplantation, autologous chondrocyte transplantation, or mosaicplasty within 12 months of screening; History of total or partial knee arthroplasty in the index knee
  • Planned/anticipated surgery of the index knee, any other surgery, or hospitalization during the study period
  • History of atherosclerotic cardiovascular disease (ASCVD) defined as prior myocardial infarction, stroke (ischaemic or haemorrhagic), transient ischemic attack, coronary revascularization (e.g., PCI, CABG), peripheral artery disease, or heart failure (NYHA Class II or higher) in the past three years; OR a calculated 10-year ASCVD risk ≥10% based on age, sex, race, total/HDL cholesterol, systolic blood pressure, diabetes, smoking status; OR current use of dual antiplatelet therapy, chronic anticoagulation (e.g., warfarin, direct oral anticoagulants), or high-dose aspirin (>300 mg/day)
  • Positive drug screen (opiates, amphetamines, cocaine metabolites, benzodiazepines, cannabinoids); Active substance abuse (drugs or alcohol), history of chronic substance abuse within the past year, or prior chronic substance abuse judged by the investigator as likely to recur during the study
  • Any condition that could confound the patient's assessment of index knee pain in judgement of the investigator (for example, peri-articular pain of any cause or secondary arthritis that involves the index knee, joint dysplasia, aseptic osteonecrosis, acromegaly, Paget's disease, Ehlers-Danlos Syndrome, Gaucher's disease, Stickler's syndrome, hemophilia, hemochromatosis, or neuropathic arthropathy, radicular lower back pain and hip pain that is referred to the knee that could cause misclassification); Other chronic pain anywhere in the body that confounds assessment of knee or that requires the use of celecoxib
  • Known hypersensitivity to any form of NSAIDs (including celecoxib), sulfonamide-containing drugs, carboxymethyl cellulose, polysorbate 80 or lidocaine; History of severe allergic reactions
  • Active or history of malignancy within the past 3 years, with the exception of resected basal cell carcinoma, squamous cell carcinoma of the knee, or effectively managed cervical carcinoma
  • Known active or quiescent systemic fungal, bacterial (including tuberculosis), viral or parasitic infections (including HIV, hepatitis B or C viruses), or ocular herpes simplex; Any infection requiring intravenous antibiotics within 2 months of screening or oral antibiotics within 2 weeks of screening; History of infection in the index knee within 12 months of screening; History of osteomyelitis
  • Active uncontrolled psychiatric disorder including psychosis (e.g. schizophrenia), bipolar disorder, uncontrolled anxiety disorder and major depressive disorder
  • Skin breakdown at the knee where the injection would take place; Any skin condition and/or tattoo that may interfere with the evaluation of safety at the injection site
  • Any other clinically significant acute or chronic medical conditions (e.g. bleeding disorder) that, in the judgement of the investigator, would preclude the use of an intra-articular NSAID or that could compromise patient safety, limit the patient's ability to complete the study, and/or compromise the objectives of the study
  • Fibromyalgia, Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, reactive arthritis, arthritis associated with inflammatory bowel disease, crystal disease of the index knee (e.g. gout or calcium pyrophosphate deposition disease), rapidly progressive osteoarthritis (defined as joint space narrowing > 1.2 mm/year), sarcoidosis or amyloidosis
  • Any clinically significant laboratory parameters or ECG abnormality as judged by the investigator
  • Uncontrolled diabetes as indicated by a hemoglobin A1c of >7.5% at screening
  • Abnormal liver function with AST or ALT > 2 upper limit of normal (ULN) at screening
  • Abnormal kidney function with eGFR < 45 mL/min/1.73m2 at screening
  • Platelet count outside normal range at screening
  • WBC count < 3500 cells/mm3 or >20000 cells/mm3 at screening
  • Malalignment of greater than 10 degrees in the femorotibial axis of the index knee on standing; Unstable joint (such as tornanterior cruciate ligament) or traumatic knee injury to the index knee (such as meniscal root tear) within 12 months of screening
  • Effusion at screening that likely requires joint aspiration for symptom relief from day 2 to day 83 during the study, as indicated by at least four joint drainages in the past year
  • Women who are pregnant or nursing; Women of child-bearing potential (not surgically sterile or post-menopausal for at least 1 year as documented in medical history) not using a highly effective method of contraception (abstinence; oral, injected or implanted hormonal methods of contraception; intrauterine device or intrauterine system; condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/cream/suppository; or male sterilization (vasectomy for at least 3 months))

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 20 és 75 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Ausztrália.

  • Cognivus Research GroupWahroonga, AusztráliaContact: Amir PapanRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study aims to understand the safety, drug concentration and distribution of an intra-articular injectable formulation of celecoxib, AVD275, in patients with knee osteoarthritis. One single injection at three different doses of the drug will be studied in a sequential order, and each participant will be monitored for 24 weeks over ten clinical visits.

A vizsgálat 3 csoportja

  • Low Dose ArmA vizsgált kezelés

    One low dose of AVD275 is injected to the osteoarthritic knee joint

    Kezelés: AVD275 Intra-articular Injection

  • Middle Dose ArmA vizsgált kezelés

    One middle dose of AVD275 is injected to the osteoarthritic knee joint

    Kezelés: AVD275 Intra-articular Injection

  • High Dose ArmA vizsgált kezelés

    One high dose of AVD275 is injected to the osteoarthritic knee joint

    Kezelés: AVD275 Intra-articular Injection

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Single Ascending Dose Study to Assess the Safety and Pharmacokinetics of Intra-articular AVD275 Injection in Patients With Osteoarthritis of the Knee
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT07338266: ki vehet részt
A regiszteradat frissítve
2026. október 20.